- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
DLBCL | Clinical
Bridging Options for CAR T-Cell Therapy in R/R DLBCL
January 06, 2023
During a Targeted Oncology case-based roundtable event, Christopher R. Flowers, MD, MS, discussed the choice of bridging therapy for a patient with relapsed/refractory diffuse large B-cell lymphoma who may receive CAR (chimeric antigen receptor) T-cell therapy. This is the second of 2 articles based on this event.
Real-World Experience With Referral and Access to CAR T-Cell Therapy
December 30, 2022
During a Targeted Oncology case-based roundtable event, Christopher R. Flowers, MD, MS, discussed with participants their experiences referring patients for chimeric antigen receptor T-cell therapy and using bridging therapy. This is the first of 2 articles based on this event.
Shifting Treatment Paradigm in DLBCL Reflects Changes for CAR T-Cell Therapy, Polatuzumab
December 20, 2022
The combination of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone is moving into the frontline setting for patients with diffuse large B-cell lymphoma.
Matasar Looks at Various Treatment Options in the DLBCL Setting for Transplant-Ineligble Patients
December 19, 2022
During a Targeted Oncology case-based roundtable event, Matthew Matasar, MD, MS, discussed the case of a patient with diffuse large B-cell lymphoma who relapsed 18 months following frontline combination therapy.
Phillips Evaluates Second-Line Therapy Options for R/R DLBCL
December 14, 2022
During a Targeted Oncology case-based roundtable event, Tycel Phillips, MD, discussed available therapies for a patient with relapsed/refractory diffuse large B-cell lymphoma including CAR T-cell therapy and combination systemic therapies.
Rapcabtagene Autoleucel Induces Responses in R/R DLBCL
December 12, 2022
ClonoSeq ctDNA-based MRD Assay Launched for Patients With DLBCL
December 05, 2022
Adaptive Biotechnologies announced the launch of its clonoSEQ ctDNA-based MRD assay for patients with diffuse large B-cell lymphoma.
Roundtable Discussion: Ayyappan Breaks Down New and Emerging Approaches in DLBCL
November 13, 2022
During a Targeted Oncology case-based roundtable event, Sabarish Ayyappan, MD, discussed with participants which therapy would be appropriate for an older patient with relapsed/refractory diffuse large B-cell lymphoma.
Westin Discusses the Evidence for Using New Therapies in R/R DLBCL
November 08, 2022
During a Targeted Oncology case-based roundtable event, Jason Westin, MD, discussed recent clinical trial data for patients with relapsed/refractory diffuse B-cell lymphoma.
Roundtable Discussion: Torka Assesses the Evidence for New and Emerging Treatment Approaches in DLBCL
October 16, 2022
During a Targeted Oncology case-based roundtable event, Pallawi Torka, MD, discussed with participants the use of novel therapies for patients with diffuse large B-cell lymphoma.